Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775990 | 1.00 | CYP2C9 (0.41) | CYP2C9CYP2D6KIF11CYP3A4CYP2C19 | |
| SCHEMBL7272215 | 0.85 | KIF11 (0.43) | CYP2C9CYP2D6KIF11CYP3A4CYP2C19 | |
| SCHEMBL1591369 | 0.84 | NOTUM (0.41) | CYP2C9CYP2D6KIF11CYP2C19MEN1 | |
| SCHEMBL3335216 | 0.81 | AR (0.41) | CYP2C9CYP2D6 | |
| SCHEMBL7266124 | 0.81 | ERN1 (0.41) | CYP2C9CYP2D6ERN1MEN1ALDH1A1 | |
| SCHEMBL7274144 | 0.78 | VCAM1 (0.41) | CYP2C9CYP2D6CYP3A4ERN1MEN1 | |
| SCHEMBL12235261 | 0.77 | ERN1 (0.42) | CYP2C9CYP2D6CYP3A4CYP2C19ERN1 | |
| SCHEMBL7266185 | 0.74 | CYP2C9 (0.41) | CYP2C9CYP2D6KIF11CYP3A4CYP2C19 | |
| SCHEMBL7932559 | 0.74 | CA1 (0.34) | CYP2C9CYP2D6KIF11 | |
| SCHEMBL9340547 | 0.74 | CYP2C9 (0.46) | CYP2C9CYP2D6KIF11CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013756-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | disclosed |
| US-20220380371-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-4013756-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021053617-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053617-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-0396987-B1 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| US-5041683-A | Nuclear-fluorinated trifluoromethylbenzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0396987-A2 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
| EP-0230110-A1 | Pharmacologically active pyrrole and pyrazole derivatives | FISONS plc (GB) | 1987-07-29 | — | — | EP | disclosed |
| EP-0174131-A2 | Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380371-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | MLLT1, BMI1, DOT1L | CYP2C9 4519/4885CYP2D6 4173/4885KIF11 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.